Skip to main content
Premium Trial:

Request an Annual Quote

Charles Dimmler, Sue Siegel, Robert Wayman, Claire Fraser-Liggett

Premium
Gene Logic last week named Charles Dimmler its new CEO. Dimmler replaces Mark Gessler, who will maintain his position as chairman of the board of directors.
 
Dimmler has been on Gene Logic’s board of directors for 10 years, and has been involved in biotechnology management and finance for 20.
 

 
Sue Siegel has resigned her post as president emeritus of Affymetrix, the company said in a Securities and Exchange Commission filing last week.
 
Affymetrix has not disclosed the reason for Siegel’s resignation or said who will replace her as president emeritus. Siegel joined the company in 1998 as vice president of sales and marketing, and was named president and appointed to the company’s board within two years.
 
Separately, Affymetrix has named Robert Wayman to its board of directors.
 
Wayman recently retired as executive vice president and CFO at Hewlett-Packard. He had also been a director at HP, Conway, and Sybase.
 

 
Claire Fraser-Liggett has resigned as president of the Institute for Genomic Research and will leave TIGR on April 20, PGx Reporter sister publication GenomeWeb Daily News reported this week.
 
It was not immediately clear who will take her place at TIGR, which is a division of the J. Craig Venter Institute.
 
News of Fraser-Liggett’s departure was disclosed in an e-mail sent to JCVI colleagues by Craig Venter, JCVI president and CEO, which said she will leave “to pursue a new position.” 
 
“We are not making a media announcement at this time because she is still in the process of final negotiations regarding her new position,” Venter said in the e-mail.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.